- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Shell Asset Management Co. Trims Stake in AbbVie Inc.
The investment firm reduced its holdings in the pharmaceutical company by over 56% in the third quarter.
Published on Feb. 15, 2026
Got story updates? Submit your updates here. ›
Shell Asset Management Co. decreased its investment in AbbVie Inc. (NYSE:ABBV) by 56.4% in the third quarter, according to a recent SEC filing. The firm now holds 22,295 shares of the pharmaceutical company's stock, valued at $5,162,000 at the end of the quarter.
Why it matters
This reduction in stake by a major institutional investor like Shell Asset Management Co. could signal a shift in sentiment around AbbVie's stock. Institutional investors closely monitor and adjust their holdings in major pharmaceutical companies like AbbVie, which can influence the stock price and market perception.
The details
According to the 13F filing, Shell Asset Management Co. sold 28,785 shares of AbbVie during the third quarter, reducing its total holdings to 22,295 shares. AbbVie comprises approximately 0.5% of Shell Asset Management Co.'s investment portfolio, making it the 21st largest position.
- The 13F filing covers the third quarter of 2026.
The players
Shell Asset Management Co.
An investment management firm that oversees a portfolio of assets on behalf of its clients.
AbbVie Inc.
A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.
The takeaway
The reduction in Shell Asset Management Co.'s stake in AbbVie could signal a broader shift in investor sentiment around the pharmaceutical company's stock. However, without further context or commentary from the investment firm, it's difficult to determine the specific reasons behind this portfolio adjustment.
